<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Ip Group — News on 6ix</title>
<link>https://6ix.com/company/ip-group</link>
<description>Latest news and press releases for Ip Group on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 21 Apr 2026 06:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/ip-group" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835e67578dffbe2df12899c.webp</url>
<title>Ip Group</title>
<link>https://6ix.com/company/ip-group</link>
</image>
<item>
<title>First Light announces £25m successful first close</title>
<link>https://6ix.com/company/ip-group/news/first-light-announces-pound25m-successful-first-close</link>
<guid isPermaLink="true">https://6ix.com/company/ip-group/news/first-light-announces-pound25m-successful-first-close</guid>
<pubDate>Tue, 21 Apr 2026 06:00:00 GMT</pubDate>
<description>IP Group plc notes that its portfolio company, First Light Fusion, has successfully completed the first close of its latest funding round, raising £25 million. This investment, led by East X Ventures and Starmaker One with significant participation from the UK Atomic Energy Authority, will accelerate the commercial development of First Light's FLARE Fusion Energy concept. IP Group currently holds a 28.3% undiluted beneficial interest in First Light, with an additional 17.3% held via its managed </description>
</item>
<item>
<title>Annual Financial Report</title>
<link>https://6ix.com/company/ip-group/news/annual-financial-report-419</link>
<guid isPermaLink="true">https://6ix.com/company/ip-group/news/annual-financial-report-419</guid>
<pubDate>Wed, 15 Apr 2026 16:00:00 GMT</pubDate>
<description>IP Group PLC has published its Annual Report and Accounts for the year ended 31 December 2025, making it available on the FCA's National Storage Mechanism and the Investor Relations section of its website. The company's Annual General Meeting is scheduled for 18 June 2026.
Disclaimer*</description>
</item>
<item>
<title>New climate fund launch with Australia's CEFC</title>
<link>https://6ix.com/company/ip-group/news/new-climate-fund-launch-with-australias-cefc</link>
<guid isPermaLink="true">https://6ix.com/company/ip-group/news/new-climate-fund-launch-with-australias-cefc</guid>
<pubDate>Mon, 30 Mar 2026 13:00:00 GMT</pubDate>
<description>IP Group plc has launched the IP Group Climate Catalyst Fund with Australia's Clean Energy Finance Corporation, aiming to raise up to A$150 million to support Australian cleantech companies focused on decarbonising hard-to-abate industries. The fund has reached its first close with IP Group contributing A$30 million and CEFC A$20 million as cornerstone investors, targeting investments in sectors such as industrial processes, heavy transport, and energy-efficient AI. This initiative aligns with I</description>
</item>
<item>
<title>IP Group plc 2025 Annual Results Release</title>
<link>https://6ix.com/company/ip-group/news/ip-group-plc-2025-annual-results-release</link>
<guid isPermaLink="true">https://6ix.com/company/ip-group/news/ip-group-plc-2025-annual-results-release</guid>
<pubDate>Tue, 17 Mar 2026 07:00:00 GMT</pubDate>
<description>IP Group PLC reported a Net Asset Value (NAV) per share increase of 13% to 110.4p, with a closing NAV of £975.1m for the year ended 31 December 2025. The company recognized £128.2m for future royalty and milestone income following Pfizer's acquisition of Metsera, benefiting from exposure to Pfizer's obesity drug franchise. Total cash proceeds from exits were £68.1m, and the company invested £70.5m across 31 companies, while raising £914m in capital for its portfolio companies. IP Group also comp</description>
</item>
<item>
<title>Portfolio company Oxa raises $103m in Series D</title>
<link>https://6ix.com/company/ip-group/news/portfolio-company-oxa-raises-dollar103m-in-series-d</link>
<guid isPermaLink="true">https://6ix.com/company/ip-group/news/portfolio-company-oxa-raises-dollar103m-in-series-d</guid>
<pubDate>Wed, 04 Mar 2026 07:00:00 GMT</pubDate>
<description>IP Group plc notes that its portfolio company Oxa Autonomy Ltd has successfully closed its Series D funding round, raising $103 million, with an initial $50 million commitment from the National Wealth Fund, alongside investments from NVentures and existing shareholders including IP Group and bp Ventures. IP Group itself invested £7.5 million ($10 million) from its balance sheet and £19 million ($25 million) from its Hostplus managed funds, increasing its undiluted beneficial holding in Oxa to 10</description>
</item>
<item>
<title>Microbiotica announces positive P1b trial results</title>
<link>https://6ix.com/company/ip-group/news/microbiotica-announces-positive-p1b-trial-results</link>
<guid isPermaLink="true">https://6ix.com/company/ip-group/news/microbiotica-announces-positive-p1b-trial-results</guid>
<pubDate>Wed, 11 Feb 2026 09:01:00 GMT</pubDate>
<description>IP Group plc notes that its portfolio company, Microbiotica, has announced positive Phase 1b trial results for its ulcerative colitis treatment, MB310. The trial met its primary and secondary objectives, demonstrating MB310's safety and tolerability, with successful engraftment of bacteria and statistically significant efficacy improvements compared to placebo. Notably, 63.2% of MB310 treated patients achieved clinical remission, and all patients entering follow-up maintained remission with comp</description>
</item>
<item>
<title>Holding(s) in Company</title>
<link>https://6ix.com/company/ip-group/news/holdings-in-company-178</link>
<guid isPermaLink="true">https://6ix.com/company/ip-group/news/holdings-in-company-178</guid>
<pubDate>Fri, 30 Jan 2026 07:00:00 GMT</pubDate>
<description>Jefferies Financial Group Inc. has increased its total holding in IP Group PLC to 5.288% as of January 28, 2026, crossing a notification threshold. This comprises 0.894% of direct voting rights attached to shares and 4.394% through various financial instruments including stock loan/repo rights of recall and multiple swap agreements with varying expiration dates through December 2026. This represents an increase from their previous notification where they held 4.432% of the company's voting right</description>
</item>
<item>
<title>Directorate change</title>
<link>https://6ix.com/company/ip-group/news/directorate-change-108</link>
<guid isPermaLink="true">https://6ix.com/company/ip-group/news/directorate-change-108</guid>
<pubDate>Wed, 14 Jan 2026 07:00:00 GMT</pubDate>
<description>IP Group plc has announced that its Chair, Sir Douglas Flint, will be stepping down from his role at the conclusion of the Group's Annual General Meeting in June 2026, as he will not stand for re-election. This decision follows his appointment as independent non-executive director and Chair designate of Prudential plc, effective March 2026. The Nomination Committee has been planning for succession, considering that several directors are approaching their nine-year term limit, and will provide fu</description>
</item>
<item>
<title>Pulmocide announces termination of Phase 3 study</title>
<link>https://6ix.com/company/ip-group/news/pulmocide-announces-termination-of-phase-3-study</link>
<guid isPermaLink="true">https://6ix.com/company/ip-group/news/pulmocide-announces-termination-of-phase-3-study</guid>
<pubDate>Wed, 07 Jan 2026 14:06:00 GMT</pubDate>
<description>IP Group plc has announced that its portfolio company, Pulmocide, has terminated its Opera-T Phase 3 Study for opelconazole due to refractory Invasive Pulmonary Aspergillosis. Pulmocide, in which IP Group holds a 12.0% stake valued at £28.1m, will review the trial data to determine future steps for the program. Consequently, IP Group expects a significant reduction in the carrying value of this asset and will conduct further evaluation as part of its year-end process to determine the appropriate</description>
</item>
<item>
<title>Total Voting Rights</title>
<link>https://6ix.com/company/ip-group/news/total-voting-rights-393</link>
<guid isPermaLink="true">https://6ix.com/company/ip-group/news/total-voting-rights-393</guid>
<pubDate>Mon, 01 Dec 2025 17:37:00 GMT</pubDate>
<description>IP Group PLC has announced its voting rights and capital as of December 1, 2025, stating that there are 883,427,642 shares in issue with no shares held in treasury, resulting in a total of 883,427,642 voting rights. This disclosure is intended to assist shareholders in determining their notification obligations under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.
Disclaimer*</description>
</item>
<item>
<title>Completion of share buyback programme</title>
<link>https://6ix.com/company/ip-group/news/completion-of-share-buyback-programme-3</link>
<guid isPermaLink="true">https://6ix.com/company/ip-group/news/completion-of-share-buyback-programme-3</guid>
<pubDate>Thu, 20 Nov 2025 07:00:00 GMT</pubDate>
<description>IP Group plc has successfully completed the £20 million extension to its share buyback programme, bringing the total aggregate consideration for the programme to £75 million, with 157,968,634 shares purchased at an average price of 47.5 pence. Following the cancellation of these shares, the company's issued share capital now stands at 883,427,642 ordinary shares with no shares held in treasury, a figure shareholders can use for regulatory notification calculations. The Group indicated that share</description>
</item>
<item>
<title>Transaction in Own Shares</title>
<link>https://6ix.com/company/ip-group/news/transaction-in-own-shares-111</link>
<guid isPermaLink="true">https://6ix.com/company/ip-group/news/transaction-in-own-shares-111</guid>
<pubDate>Wed, 19 Nov 2025 07:00:00 GMT</pubDate>
<description>IP Group plc has announced the repurchase of 366,813 ordinary shares on November 18, 2025, as part of its ongoing share buyback program. The shares were acquired at a volume-weighted average price of 60.3048 pence, with the highest price paid being 60.60 pence and the lowest at 59.80 pence. Following this transaction and subsequent cancellation, the total number of ordinary shares in issue with voting rights is now 883,427,642.
Disclaimer*</description>
</item>
<item>
<title>Artios completes oversubscribed $115m financing</title>
<link>https://6ix.com/company/ip-group/news/artios-completes-oversubscribed-dollar115m-financing</link>
<guid isPermaLink="true">https://6ix.com/company/ip-group/news/artios-completes-oversubscribed-dollar115m-financing</guid>
<pubDate>Mon, 17 Nov 2025 13:10:00 GMT</pubDate>
<description>IP Group plc announced that its portfolio company, Artios Pharma Ltd, has successfully completed an oversubscribed Series D financing round, raising $115 million. IP Group invested £5.5 million in this round and now holds a 6.8% stake in Artios. The funds will be used to advance Artios' lead program, alnodesertib, in clinical trials for pancreatic and colorectal cancers, and to initiate a Phase 2 trial for its second candidate, ART6043, in breast cancer.
Disclaimer*</description>
</item>
<item>
<title>Potential income from Metsera obesity drugs</title>
<link>https://6ix.com/company/ip-group/news/potential-income-from-metsera-obesity-drugs</link>
<guid isPermaLink="true">https://6ix.com/company/ip-group/news/potential-income-from-metsera-obesity-drugs</guid>
<pubDate>Mon, 13 Oct 2025 06:00:00 GMT</pubDate>
<description>IP Group PLC has provided an update on potential future revenue from Metsera's obesity drug candidates, following Pfizer's agreement to acquire Metsera for up to $7.3 billion, including $4.9 billion upfront. IP Group benefits from exposure to Metsera's programs, including MET-097i, MET-233, MET-034 and MET-067, through its prior ownership and licensing of Zihipp IP. IP Group is entitled to future returns via milestone payments and low-single digit percentage royalties on net sales of licensed pr</description>
</item>
<item>
<title>Portfolio co Monolith to be acquired by CoreWeave</title>
<link>https://6ix.com/company/ip-group/news/portfolio-co-monolith-to-be-acquired-by-coreweave</link>
<guid isPermaLink="true">https://6ix.com/company/ip-group/news/portfolio-co-monolith-to-be-acquired-by-coreweave</guid>
<pubDate>Wed, 08 Oct 2025 06:00:00 GMT</pubDate>
<description>IP Group PLC announced on October 8, 2025, that its portfolio company, Monolith Ltd, is being acquired by CoreWeave, Inc. IP Group holds a 12.3% stake in Monolith, an AI software provider for engineering teams. While the financial terms of the acquisition remain undisclosed, the closing of the transaction is contingent upon customary closing conditions. CoreWeave's acquisition of Monolith aims to expand its AI cloud platform into industrial innovation, potentially increasing R&D efficiency by 20</description>
</item>
<item>
<title>Portfolio co OXCCU completes £20.75m funding round</title>
<link>https://6ix.com/company/ip-group/news/portfolio-co-oxccu-completes-pound2075m-funding-round</link>
<guid isPermaLink="true">https://6ix.com/company/ip-group/news/portfolio-co-oxccu-completes-pound2075m-funding-round</guid>
<pubDate>Mon, 29 Sep 2025 06:00:00 GMT</pubDate>
<description>Portfolio co OXCCU completes £20.75m funding round.</description>
</item>
<item>
<title>Half-yearly results 2025</title>
<link>https://6ix.com/company/ip-group/news/half-yearly-results-2025</link>
<guid isPermaLink="true">https://6ix.com/company/ip-group/news/half-yearly-results-2025</guid>
<pubDate>Wed, 17 Sep 2025 06:00:00 GMT</pubDate>
<description>IP Group PLC announced its half-yearly results for 2025, highlighting portfolio developments and maintained financial strength. The company reported total cash proceeds from exits of £30.3m, a ninefold increase compared to HY24. The Net Asset Value (NAV) per share was 96.2p, with a closing NAV of £883.1m; however, NAV per share reached approximately 100p by September 12, 2025. The portfolio raised £372m in total capital. IP Group invested £36m across 21 companies. Gross cash reached £237.3m, a 4</description>
</item>
<item>
<title>Notice of Results</title>
<link>https://6ix.com/company/ip-group/news/notice-of-results-49</link>
<guid isPermaLink="true">https://6ix.com/company/ip-group/news/notice-of-results-49</guid>
<pubDate>Tue, 02 Sep 2025 08:00:00 GMT</pubDate>
<description>IP Group PLC will release its financial results for the six months ending June 30, 2025, on Wednesday, September 17, 2025. The results will be accessible via the London Stock Exchange's Regulatory News Service and on the Investor Relations section of the company's website. A live presentation by key members of IP Group's leadership team will be held on the Investor Meet Company platform on September 17, 2025, at 10 am. Questions for the presentation can be submitted in advance until 9 am the day</description>
</item>
<item>
<title>Istesso data demonstrate tissue repair</title>
<link>https://6ix.com/company/ip-group/news/istesso-data-demonstrate-tissue-repair</link>
<guid isPermaLink="true">https://6ix.com/company/ip-group/news/istesso-data-demonstrate-tissue-repair</guid>
<pubDate>Thu, 17 Jul 2025 06:01:00 GMT</pubDate>
<description>Istesso data demonstrate tissue repair.</description>
</item>
<item>
<title>Share buyback programme update</title>
<link>https://6ix.com/company/ip-group/news/share-buyback-programme-update</link>
<guid isPermaLink="true">https://6ix.com/company/ip-group/news/share-buyback-programme-update</guid>
<pubDate>Thu, 26 Jun 2025 15:19:00 GMT</pubDate>
<description>Share buyback programme update.</description>
</item>
</channel>
</rss>